How would you approach a patient whose stage II TNBC tumor is visibly progressing on the KN-522 neoadjuvant regimen?

Yes, in a patient whose TNBC is visibly progressing on neoadjuvant chemotherapy, I would change course by either changing regimen or proceeding with local management. The CR rate to the KEYNOTE 522 regimen is impressive (64.8% with pembo vs 51.2% without pembro; Schmid et al., PMID 32101663), but this does supplant general principles in management with neoadjuvant chemotherapy for breast cancer. The other question here, to which we do not know the answer, is whether or not to continue pembrolizu...

Continue Pembrolizumab after local therapy:- KEYNOTE-522.